The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...

Cortisone injections are commonly used to treat a variety of orthopedic conditions. People with diabetes are especially prone to side effects from cortisone injections, often experiencing a temporary ...

The safety profile of dupilumab in EoE founded to be consistent with other atopic disease, both in adults and children. Injection site reactions, rhinopharyngitis, headache and nausea were the more ...

Dupilumab (REGN-668, SAR231893, Dupixent, Dubrantis) is a monoclonal antibody produced by recombinant DNA technology. It is formulated as an injectable solution for subcutaneous route of ...

Dupilumab (REGN-668, SAR231893, Dupixent, Dubrantis) is a monoclonal antibody produced by recombinant DNA technology. It is formulated as an injectable solution for subcutaneous route of ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone for ...

Sanofi’s chief executive Paul Hudson discussed the success of Dupixent (dupilumab)and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and ...

Inclusion criteria: (1) Children and adolescents aged 6 months to younger than 18 years; (2) Pediatric patients treated with dupilumab injection (300 mg/2.0 ml/vial or 200 mg/1.14 ml/vial pre-filled ...